The development of new drugs is an expensive process that requires extensive testing of a drug's mechanism of action and safety. The Principal Investigator proposes to explore the possibility of using a genetic approach to identify cellular components that affect the activity of therapeutic compounds. Such components may include primary or secondary drug targets, or proteins that metabolize or transport a given drug. As a test case, the Principal Investigator will take advantage of the inhibition of cellular proliferation by anti-hypertensive calcium channel blockers to isolate gene products that are important to the action of these drugs. These preliminary studies will determine the feasibility of employing this approach on a large scale to compounds in development or to drugs whose pharmacology is incompletely understood.
NOT AVAILABLE
| Lastro, Michele; Kourtidis, Antonis; Farley, Kate et al. (2008) xCT expression reduces the early cell cycle requirement for calcium signaling. Cell Signal 20:390-9 |
